{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:56:47Z","timestamp":1791921407949,"version":"4.3.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2012,11,25]],"date-time":"2012-11-25T00:00:00Z","timestamp":1353801600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Biotechnol"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1038\/nbt.2436","type":"journal-article","created":{"date-parts":[[2012,11,18]],"date-time":"2012-11-18T18:59:53Z","timestamp":1353265193000},"page":"1210-1216","source":"Crossref","is-referenced-by-count":451,"title":["Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection"],"prefix":"10.1038","volume":"30","author":[{"given":"Benjamin","family":"Petsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margit","family":"Schnee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette B","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Voss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schlake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Thess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl-Josef","family":"Kallen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lothar","family":"Stitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kramps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,11,25]]},"reference":[{"key":"BFnbt2436_CR1","unstructured":"Plotkin, S.A., Orenstein, W.A. & Offit, P.A. Vaccines: Expert Consult (Saunders, 2008)."},{"key":"BFnbt2436_CR2","first-page":"1","volume":"59","author":"AE Fiore","year":"2010","unstructured":"Fiore, A.E. et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm. Rep. 59, 1\u201362 (2010).","journal-title":"MMWR Recomm. Rep."},{"key":"BFnbt2436_CR3","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/ni1343","volume":"7","author":"PC Doherty","year":"2006","unstructured":"Doherty, P.C., Turner, S.J., Webby, R.G. & Thomas, P.G. Influenza and the challenge for immunology. Nat. Immunol. 7, 449\u2013455 (2006).","journal-title":"Nat. Immunol."},{"key":"BFnbt2436_CR4","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.cell.2009.01.029","volume":"136","author":"R Salomon","year":"2009","unstructured":"Salomon, R. & Webster, R.G. The influenza virus enigma. Cell 136, 402\u2013410 (2009).","journal-title":"Cell"},{"key":"BFnbt2436_CR5","unstructured":"Knipe, D.M., Howley, P.M., Griffin, D.E., Lamb, R.A. & Martin, M.A. Fields Virology (Lippincott Williams & Wilkins, 2006)."},{"key":"BFnbt2436_CR6","doi-asserted-by":"publisher","first-page":"4269","DOI":"10.1073\/pnas.1116200109","volume":"109","author":"S Tong","year":"2012","unstructured":"Tong, S. et al. A distinct lineage of influenza A virus from bats. Proc. Natl. Acad. Sci. USA 109, 4269\u20134274 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnbt2436_CR7","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/(SICI)1096-9071(200005)61:1<94::AID-JMV15>3.0.CO;2-C","volume":"61","author":"JC de Jong","year":"2000","unstructured":"de Jong, J.C., Beyer, W.E., Palache, A.M., Rimmelzwaan, G.F. & Osterhaus, A.D. Mismatch between the 1997\/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J. Med. Virol. 61, 94\u201399 (2000).","journal-title":"J. Med. Virol."},{"key":"BFnbt2436_CR8","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1038\/nbt1261","volume":"24","author":"JB Ulmer","year":"2006","unstructured":"Ulmer, J.B., Valley, U. & Rappuoli, R. Vaccine manufacturing: challenges and solutions. Nat. Biotechnol. 24, 1377\u20131383 (2006).","journal-title":"Nat. Biotechnol."},{"key":"BFnbt2436_CR9","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1056\/NEJMra1002842","volume":"363","author":"LC Lambert","year":"2010","unstructured":"Lambert, L.C. & Fauci, A.S. Influenza vaccines for the future. N. Engl. J. Med. 363, 2036\u20132044 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnbt2436_CR10","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1038\/nm1210-1389","volume":"16","author":"GJ Nabel","year":"2010","unstructured":"Nabel, G.J. & Fauci, A.S. Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. Nat. Med. 16, 1389\u20131391 (2010).","journal-title":"Nat. Med."},{"key":"BFnbt2436_CR11","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/nbt0905-1059","volume":"23","author":"GM Forde","year":"2005","unstructured":"Forde, G.M. Rapid-response vaccines\u2014does DNA offer a solution? Nat. Biotechnol. 23, 1059\u20131062 (2005).","journal-title":"Nat. Biotechnol."},{"key":"BFnbt2436_CR12","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.immuni.2010.10.004","volume":"33","author":"MA Liu","year":"2010","unstructured":"Liu, M.A. Immunologic basis of vaccine vectors. Immunity 33, 504\u2013515 (2010).","journal-title":"Immunity"},{"key":"BFnbt2436_CR13","doi-asserted-by":"crossref","unstructured":"Thalhamer, J., Weiss, R. & Scheiblhofer, S. Gene Vaccines (Springer, Wien and New York; 2011).","DOI":"10.1007\/978-3-7091-0439-2"},{"key":"BFnbt2436_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/1521-4141(200001)30:1<1::AID-IMMU1>3.0.CO;2-#","volume":"30","author":"I Hoerr","year":"2000","unstructured":"Hoerr, I., Obst, R., Rammensee, H.G. & Jung, G. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur. J. Immunol. 30, 1\u20137 (2000).","journal-title":"Eur. J. Immunol."},{"key":"BFnbt2436_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CJI.0b013e3181f7dbe8","volume":"34","author":"M Fotin-Mleczek","year":"2011","unstructured":"Fotin-Mleczek, M. et al. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J. Immunother. 34, 1\u201315 (2011).","journal-title":"J. Immunother."},{"issue":"15_suppl","key":"BFnbt2436_CR16","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1200\/jco.2011.29.15_suppl.2584","volume":"29","author":"M. Sebastian","year":"2011","unstructured":"Sebastian, M. et al. Messenger RNA vaccination in NSCLC: findings from a phase I\/IIa clinical trial. J. Clin. Oncol. 29 (suppl; abstr 2584) (2011).","journal-title":"Journal of Clinical Oncology"},{"issue":"15_suppl","key":"BFnbt2436_CR17","doi-asserted-by":"publisher","first-page":"4535","DOI":"10.1200\/jco.2011.29.15_suppl.4535","volume":"29","author":"H. K\u00fcbler","year":"2011","unstructured":"K\u00fcbler, H. et al. Final analysis of a phase I\/IIa study with CV9103, an intradermally administered prostate cancer immunotherapy based on self-adjuvanted mRNA. J. Clin. Oncol. 29 (suppl; abstr 4535) (2011).","journal-title":"Journal of Clinical Oncology"},{"key":"BFnbt2436_CR18","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1093\/oxfordjournals.bmb.a071545","volume":"35","author":"CW Potter","year":"1979","unstructured":"Potter, C.W. & Oxford, J.S. Determinants of immunity to influenza infection in man. Br. Med. Bull. 35, 69\u201375 (1979).","journal-title":"Br. Med. Bull."},{"key":"BFnbt2436_CR19","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1086\/589862","volume":"47","author":"SA Plotkin","year":"2008","unstructured":"Plotkin, S.A. Vaccines: correlates of vaccine-induced immunity. Clin. Infect. Dis. 47, 401\u2013409 (2008).","journal-title":"Clin. Infect. Dis."},{"key":"BFnbt2436_CR20","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.4049\/jimmunol.177.5.2888","volume":"177","author":"DM Brown","year":"2006","unstructured":"Brown, D.M., Dilzer, A.M., Meents, D.L. & Swain, S.L. CD4 T cell-mediated protection from lethal influenza: perforin and antibody-mediated mechanisms give a one-two punch. J. Immunol. 177, 2888\u20132898 (2006).","journal-title":"J. Immunol."},{"key":"BFnbt2436_CR21","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.1073\/pnas.0813390106","volume":"106","author":"G Galli","year":"2009","unstructured":"Galli, G. et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc. Natl. Acad. Sci. USA 106, 3877\u20133882 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnbt2436_CR22","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.4049\/jimmunol.0801814","volume":"182","author":"H Hamada","year":"2009","unstructured":"Hamada, H. et al. Tc17, a unique subset of CD8 T cells that can protect against lethal influenza challenge. J. Immunol. 182, 3469\u20133481 (2009).","journal-title":"J. Immunol."},{"key":"BFnbt2436_CR23","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/nm.2612","volume":"18","author":"TM Wilkinson","year":"2012","unstructured":"Wilkinson, T.M. et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat. Med. 18, 274\u2013280 (2012).","journal-title":"Nat. Med."},{"key":"BFnbt2436_CR24","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.4049\/jimmunol.158.4.1507","volume":"158","author":"Y Deng","year":"1997","unstructured":"Deng, Y., Yewdell, J.W., Eisenlohr, L.C. & Bennink, J.R. MHC affinity, peptide liberation, T cell repertoire, and immunodominance all contribute to the paucity of MHC class I-restricted peptides recognized by antiviral CTL. J. Immunol. 158, 1507\u20131515 (1997).","journal-title":"J. Immunol."},{"key":"BFnbt2436_CR25","doi-asserted-by":"publisher","first-page":"7662","DOI":"10.1128\/JVI.02444-09","volume":"84","author":"ACM Boon","year":"2010","unstructured":"Boon, A.C.M. et al. Cross-reactive neutralizing antibodies directed against pandemic H1N1 2009 virus are protective in a highly sensitive DBA\/2 mouse influenza model. J. Virol. 84, 7662\u20137667 (2010).","journal-title":"J. Virol."},{"key":"BFnbt2436_CR26","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJM198307073090103","volume":"309","author":"AJ McMichael","year":"1983","unstructured":"McMichael, A.J., Gotch, F.M., Noble, G.R. & Beare, P.A. Cytotoxic T-cell immunity to influenza. N. Engl. J. Med. 309, 13\u201317 (1983).","journal-title":"N. Engl. J. Med."},{"key":"BFnbt2436_CR27","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1126\/science.8456302","volume":"259","author":"JB Ulmer","year":"1993","unstructured":"Ulmer, J.B. et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259, 1745\u20131749 (1993).","journal-title":"Science"},{"key":"BFnbt2436_CR28","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.copbio.2007.11.002","volume":"18","author":"GF Rimmelzwaan","year":"2007","unstructured":"Rimmelzwaan, G.F., Fouchier, R.A.M. & Osterhaus, A.D.M.E. Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development. Curr. Opin. Biotechnol. 18, 529\u2013536 (2007).","journal-title":"Curr. Opin. Biotechnol."},{"key":"BFnbt2436_CR29","doi-asserted-by":"publisher","first-page":"e9349","DOI":"10.1371\/journal.pone.0009349","volume":"5","author":"O Kistner","year":"2010","unstructured":"Kistner, O. et al. A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models. PLoS ONE 5, e9349 (2010).","journal-title":"PLoS ONE"},{"key":"BFnbt2436_CR30","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/BF01591484","volume":"15","author":"I Chaloupka","year":"1996","unstructured":"Chaloupka, I., Schuler, A., Marschall, M. & Meier-Ewert, H. Comparative analysis of six European influenza vaccines. Eur. J. Clin. Microbiol. Infect. Dis. 15, 121\u2013127 (1996).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"BFnbt2436_CR31","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/sj.clpt.6100419","volume":"82","author":"RB Belshe","year":"2007","unstructured":"Belshe, R.B. Translational research on vaccines: influenza as an example. Clin. Pharmacol. Ther. 82, 745\u2013749 (2007).","journal-title":"Clin. Pharmacol. Ther."},{"key":"BFnbt2436_CR32","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1586\/14760584.7.6.783","volume":"7","author":"JW van der Laan","year":"2008","unstructured":"van der Laan, J.W. et al. Animal models in influenza vaccine testing. Expert Rev. Vaccines 7, 783\u2013793 (2008).","journal-title":"Expert Rev. Vaccines"},{"key":"BFnbt2436_CR33","doi-asserted-by":"publisher","first-page":"4479","DOI":"10.1016\/S0264-410X(01)00206-7","volume":"19","author":"K Van Reeth","year":"2001","unstructured":"Van Reeth, K., Labarque, G., De Clercq, S. & Pensaert, M. Efficacy of vaccination of pigs with different H1N1 swine influenza viruses using a recent challenge strain and different parameters of protection. Vaccine 19, 4479\u20134486 (2001).","journal-title":"Vaccine"},{"key":"BFnbt2436_CR34","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.vaccine.2011.12.083","volume":"30","author":"H-M Pyo","year":"2012","unstructured":"Pyo, H.-M. et al. Pandemic H1N1 influenza virus-like particles are immunogenic and provide protective immunity to pigs. Vaccine 30, 1297\u20131304 (2012).","journal-title":"Vaccine"},{"key":"BFnbt2436_CR35","doi-asserted-by":"publisher","first-page":"e32400","DOI":"10.1371\/journal.pone.0032400","volume":"7","author":"EA Lefevre","year":"2012","unstructured":"Lefevre, E.A. et al. Immune responses in pigs vaccinated with adjuvanted and non-adjuvanted A(H1N1)pdm\/09 influenza vaccines used in human immunization programmes. PLoS ONE 7, e32400 (2012).","journal-title":"PLoS ONE"},{"key":"BFnbt2436_CR36","doi-asserted-by":"publisher","first-page":"8833","DOI":"10.1016\/j.vaccine.2007.10.020","volume":"25","author":"PE Laurent","year":"2007","unstructured":"Laurent, P.E. et al. Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. Vaccine 25, 8833\u20138842 (2007).","journal-title":"Vaccine"},{"key":"BFnbt2436_CR37","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.tibtech.2008.08.002","volume":"26","author":"PR Dormitzer","year":"2008","unstructured":"Dormitzer, P.R., Ulmer, J.B. & Rappuoli, R. Structure-based antigen design: a strategy for next generation vaccines. Trends Biotechnol. 26, 659\u2013667 (2008).","journal-title":"Trends Biotechnol."},{"key":"BFnbt2436_CR38","doi-asserted-by":"publisher","first-page":"e29732","DOI":"10.1371\/journal.pone.0029732","volume":"7","author":"DX Johansson","year":"2012","unstructured":"Johansson, D.X., Ljungberg, K., Kakoulidou, M. & Liljestr\u00f6m, P. Intradermal electroporation of naked replicon RNA elicits strong immune responses. PLoS ONE 7, e29732 (2012).","journal-title":"PLoS ONE"},{"key":"BFnbt2436_CR39","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/jgm.2605","volume":"14","author":"M Fotin-Mleczek","year":"2012","unstructured":"Fotin-Mleczek, M. et al. Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect. J. Gene Med. 14, 428\u2013439 (2012).","journal-title":"J. Gene Med."},{"issue":"11","key":"BFnbt2436_CR40","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.4161\/rna.22269","volume":"9","author":"Thomas Schlake","year":"2012","unstructured":"Schlake, T. et al. Developing mRNA-vaccine technologies. RNA Biol. (in the press) (2012).","journal-title":"RNA Biology"},{"key":"BFnbt2436_CR41","first-page":"23","volume":"127","author":"S Pascolo","year":"2006","unstructured":"Pascolo, S. Vaccination with messenger RNA. Methods Mol. Med. 127, 23\u201340 (2006).","journal-title":"Methods Mol. Med."},{"key":"BFnbt2436_CR42","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/978-3-540-72167-3_11","volume-title":"Toll-Like Receptors (TLRs) and Innate Immunity","author":"Steve Pascolo","year":"2008","unstructured":"Pascolo, S. Vaccination with messenger RNA (mRNA). Handb. Exp. Pharmacol. 221\u2013235 (2008) doi:10.1007\/978-3-540-72167-3_11."},{"key":"BFnbt2436_CR43","first-page":"493","volume":"27","author":"LJ Reed","year":"1938","unstructured":"Reed, L.J. & Muench, H. A simple method of estimation of fifty percent end points. Am. J. Hyg. 27, 493\u2013497 (1938).","journal-title":"Am. J. Hyg."},{"key":"BFnbt2436_CR44","doi-asserted-by":"publisher","first-page":"4442","DOI":"10.1128\/JVI.02717-09","volume":"84","author":"R Hai","year":"2010","unstructured":"Hai, R. et al. PB1-F2 expression by the 2009 pandemic H1N1 influenza virus has minimal impact on virulence in animal models. J. Virol. 84, 4442\u20134450 (2010).","journal-title":"J. Virol."},{"key":"BFnbt2436_CR45","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/312548a0","volume":"312","author":"SP Cobbold","year":"1984","unstructured":"Cobbold, S.P., Jayasuriya, A., Nash, A., Prospero, T.D. & Waldmann, H. Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature 312, 548\u2013551 (1984).","journal-title":"Nature"},{"key":"BFnbt2436_CR46","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1099\/vir.0.014480-0","volume":"90","author":"E Lange","year":"2009","unstructured":"Lange, E. et al. Pathogenesis and transmission of the novel swine-origin influenza virus A\/H1N1 after experimental infection of pigs. J. Gen. Virol. 90, 2119\u20132123 (2009).","journal-title":"J. Gen. Virol."},{"key":"BFnbt2436_CR47","first-page":"286","volume":"123","author":"B Hoffmann","year":"2010","unstructured":"Hoffmann, B. et al. New real-time reverse transcriptase polymerase chain reactions facilitate detection and differentiation of novel A\/H1N1 influenza virus in porcine and human samples. Berl. Munch. Tierarztl. Wochenschr. 123, 286\u2013292 (2010).","journal-title":"Berl. Munch. Tierarztl. Wochenschr."}],"container-title":["Nature Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nbt.2436.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nbt.2436","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nbt.2436.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T21:03:07Z","timestamp":1687813387000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nbt.2436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,25]]},"references-count":47,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["BFnbt2436"],"URL":"https:\/\/doi.org\/10.1038\/nbt.2436","relation":{},"ISSN":["1087-0156","1546-1696"],"issn-type":[{"value":"1087-0156","type":"print"},{"value":"1546-1696","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,25]]}}}